Back to results
US 11,891,450 B2Granted
Anti-CD47 agent-based treatment of CD20-positive cancer
AssigneeForty Seven, Inc.
InventorsMark Ping Chao, Chris Hidemi Mizufune Takimoto, Jens-Peter Volkmer
Life of this patent
Estimating the term…
Abstract
Methods, kits, and compositions are provided herein that can be used to treat CD20+ cancer using an anti-CD47 agent such as an antibody. The anti-CD47 agent can be used alone or in combination with one or more additional agent such as an anti-CD20 antibody.
Claims20
A method of effectively treating or reducing cancer burden with an overall response rate of at least 40% in human subjects, wherein the human subjects have Non-Hodgkin's lymphoma (NHL) and are refractory to rituximab, comprising:
- (a) determining, before administering steps, that the human subjects are refractory to rituximab;
- (b) selecting the refractory subjects for treatment;
- (c) administering to the refractory subjects for four weeks a first cycle comprising (1) a priming dose of anti-CD47 antibody at about 1 mg of antibody per kg of body weight at time 0 (T0), (2) a dose of at least 30 mg of the anti-CD47 antibody per kg of body weight once every week beginning one week after TO, and (3) a dose of 375 mg/m2 of anti-CD20 antibody once every week;
- and
- (d) administering to the refractory subjects for four weeks a second cycle comprising (1) a dose of at least 30 mg of the anti-CD47 antibody per kg of body weight once every two weeks, and (2) a dose of 375 mg/m2 of the anti-CD20 antibody once every four weeks;
- thereby effectively treating or reducing cancer burden in the refractory subjects such that an overall response rate (ORR) of at least 40% is achieved.
3 more elements
Dependencies are inferred from the claim text.